YL201 vs. chemo for advanced esophageal cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced esophageal squamous cell carcinoma that cannot be removed with surgery or has spread to other parts of the body.
- You have already received one standard treatment for advanced disease, and the cancer has progressed.
- You are willing to provide a tumor tissue sample (from a previous biopsy or a new one).
- You have at least one tumor that can be measured on scans.
- You have not had any other cancer in the last 5 years (except for some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
This study is testing a new drug, FH-006, against the doctor's choice of chemotherapy for people with advanced esophageal cancer that has worsened after previous treatment with a PD-1/PD-L1 inhibitor plus platinum-based chemo. The goal is to see if FH-006 works better than standard chemo options.
This study compares a new drug called SYS6010 with standard chemotherapy for advanced esophageal squamous cell carcinoma that has progressed after prior treatment. It may be an option if you have this specific type of esophageal cancer and are looking for a new treatment approach.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.